As demand for CAR T therapies grows, modular platforms are offering process development teams new ways to improve cell expansion, recovery and scale-up. Chimeric antigen receptor (CAR) T cell ...

After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...

Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...

HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out ...

EASYGEN – Easy Workflow Integration for Gene Therapy is a five-year European public-private partnership supported by the Innovative Health Initiative (IHI) ...

The remarkable clinical success of CAR T therapies in blood cancers has validated the promise of engineered cell therapies. But according to Adam Janvier, PhD, head of cell therapy at eXmoor Pharma, ...

Chimeric antigen receptor T cell (CAR T) therapies have transformed the treatment of blood cancers, delivering durable responses in patients with limited options. But CAR T therapies are complex and ...

Immune cells that are engineered to attack cancer cells, known as CAR-T cells, are used to treat some types of blood cancer.

Cellares and Cabaletta Bio have reached a key clinical milestone. The companies announced April 14 dosing the first two patients with rese-cel. Cellares’ automated Cell Shuttle platform manufactured ...

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and ...